We have now compared the outcomes of 65 patients who received autologous stem cell treatment for multiple myeloma in the DGD group with the outcomes in 52 patients with the disease who routinely received G-CSF daily from day 7 (conventional G-CSF dosing—CGD). The gene discussed is CSF3; the disease is plasma cell myeloma.